Citing 'substantial benefit' for patients, Sanofi hiked Flublok price 12.5% last season

Amid an industrywide look into pharma's pricing, Sanofi has pledged to limit its drug price hikes to the rate of medical inflation. The company recently tweaked its policy to provide rationale for any hikes above that level, and in the first year of the policy, detailed a 12.5% increase for a flu shot picked up through M&A.